FDA Says It Does Not Expect AstraZeneca’s COVID-19 Antibody Treatment To Protect Against Omicron Subvariant XBB.1.5

Reuters (1/6, Satija) reported the “Food and Drug Administration said on Friday it does not expect AstraZeneca’s COVID-19 antibody cocktail” tixagevimab/cilgavimab (Evusheld) “to provide protection against the Omicron subvariant XBB.1.5.” While the FDA “i...